

ALVENTA PHARMA LIMITED

VILL. KISHANPURA, TEHSIL BADDI- NALAGARH ROAD, DISTT.- SOLAN (H.P) 174101

Quality Control Department

CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Product Name	Clindacan 300	A.R. No.	FG/G/24A0042
Generic Name	Clindamycin Injection IP 150 mg/ml	Sample Quantity	65Ampoules
Batch No.:	AA40508	Sample Received on	29/05/2024
Batch Size:	25,500 Amp.	Analysis Date	29/05/2024
Mfg. Date.	05/2024	Release Date	12/06/2024
Exp. Date	04/2027	Page No.:	Page 1 of 1

Sr. No.	Test Parameter	Acceptance Criteria		Result			
1.	Description	A clear and colourless liquid filled in 2		A clear and colourless liquid filled in 2			
		ml clear glas	ml clear glass ampoule.		ml clear glass ampoule.		
2.	Identification:						
	obticom chr refe		The principal spot in the chromatogram obtained with the test solution corresponds to the principal spot in the chromatogram obtained with the deference solution.		Complies		
	B. By HPLC	In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).		Complies			
3.	pН	Between 5.5 to 7.0		6.54			
4.	Extractable volume	Not less than 2.0 ml		2.05 ml			
5.	Particulate Matter	The Solution should be clear, colourless and free from any visible particle.		The Solution is clear, colourless and free from any visible particle.			
6.	Sterility	Should be ste	ould be sterile.		Sterile		
7.	Bacterial Endotoxins Tests	Not more Clindamycin.	bess than 0.0 Eo/ini of Childaniyen.		amycin.		
8.	Assay:						
	Each ml contains:	Claim	Limit		mg	0/0	
	Clindamycin Phosphate Eq. to Clindamycin	IP 150 mg	77		148.20 mg	98.80%	
	Benzyl Alcohol (As Preservative)		Between 90.0% to 110.0% of Stated amount of Benzyl Alcohol. (Between 0.81 %w/v to 0.99 %w/v)		0.9114%w/v	101.27%	

Remarks: The above test parameters are complies/ not complies as per IP/BP/USP & In-House Specification.

Prepared By	Checked By	Approved By
Brances Kinned	DURGESH KUMAR	Craytan singl
	Oc Heard	Head-BA
P	100	The contract of the contract o
12/26/2024	12/06/2024	12/06/9024
	Praveen Kumar Executive	Braven Kumar DURGESH KUMAR